ストックスクリーナーアプリを入手
2.51
0.00%
0.00
アフターアワーズ：
2.45
-0.06
-2.39%
Context Therapeutics Inc (CNTX) 最新ニュース
Targets Report: Can Context Therapeutics Inc maintain sales growth2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Rally Mode: What makes Context Therapeutics Inc stock attractive todayWeekly Trend Recap & Stock Market Timing Techniques - baoquankhu1.vn
Is Context Therapeutics Inc likely to announce a buybackMarket Activity Report & Safe Entry Zone Identification - baoquankhu1.vn
History Review: What is Context Therapeutics Incs 5 year growth outlookTrade Analysis Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CNTX Earnings History & Surprises | EPS & Revenue Results | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Investment Report: Will Context Therapeutics Inc stock go up in YEAR2026 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Neogen names Jennifer Evans Stacey as chief legal officer - Investing.com
Food safety company Neogen taps biotech lawyer for legal, compliance post - Stock Titan
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - MSN
Breakouts Watch: How does Context Therapeutics Inc compare to its peers2026 Earnings Surprises & Growth Focused Entry Point Reports - baoquankhu1.vn
JonesTrading Remains a Buy on Context Therapeutics (CNTX) - The Globe and Mail
Buyout Rumor: Is Context Therapeutics Inc stock risky to hold now2026 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
JonesTrading Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Context Therapeutics Gains FDA Fast Track for CTIM-76 - The Globe and Mail
Published on: 2026-04-03 00:59:30 - baoquankhu1.vn
Context Therapeutics Shares Gain on FDA Fast Track Designation for Ovarian Cancer Drug - marketscreener.com
Context Therapeutics wins FDA fast-track status (CNTX:NASDAQ) - Seeking Alpha
Context Therapeutics' CTIM-76 Wins FDA Fast Track; Phase 1a Interim Data Due June 2026 - TradingView — Track All Markets
FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - The Manila Times
Context Therapeutics Announces CTIM-76 Receives FDA Fast - GlobeNewswire
FDA fast-tracks Context drug for hard-to-treat ovarian cancer - Stock Titan
S P Trends: Can Context Therapeutics Inc maintain sales growth2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Support Test: Will Context Therapeutics Inc stock go up in YEARLayoff News & Fast Entry Momentum Alerts - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Q1 EPS Forecast for Context Therapeutics Lowered by Analyst - MarketBeat
Gains Recap: What makes Context Therapeutics Inc stock attractive todayPortfolio Value Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Insider Sell: Is Context Therapeutics Inc stock risky to hold now2026 Historical Comparison & Real-Time Volume Trigger Notifications - baoquankhu1.vn
HC Wainwright Brokers Reduce Earnings Estimates for CNTX - MarketBeat
Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) Head-To-Head Contrast - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital - Defense World
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Price Target Raised to $7.00 - MarketBeat
Context Therapeutics 2025 Annual Report: Business Strategy, Risk Factors, Clinical Pipeline, and Regulatory Insights - Minichart
Context Therapeutics Reports Full Year 2025 Operating and Financial Results - National Today
According to the latest financial data, biopharmaceutical company Context Therapeutics Inc. (Context Therapeutics) held total cash and cash equivalents of $66 million as of December 31, 2025. - Bitget
Context Therapeutics Highlights Evolving T Cell Engager Pipeline - TipRanks
Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results - MarketBeat
Context Therapeutics Reports Full Year 2025 Operating And Financial Results - TradingView
Context Therapeutics Inc. Reports Financial Results and Upcoming Milestones for CTIM-76 and CT-95 Trials - Quiver Quantitative
Context updates corporate presentation, flags interim CTIM-76/CT-95/CT-202 milestones; cash runway into mid-2027 - tradingview.com
Context Therapeutics (NASDAQ: CNTX) outlines T‑cell engager trials and cash runway - Stock Titan
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) EstimateContext Therapeutics (NASDAQ:CNTX) - Benzinga
With $66M left, Context targets 2 cancer trial updates in 2026 - Stock Titan
CNTX: Net loss rose to $36.1M in 2025; $66M cash funds operations into mid-2027, more capital needed - tradingview.com
Context Therapeutics (NASDAQ: CNTX) advances three T cell engager programs - Stock Titan
Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Surprises Report: How does Bausch Health Companies Inc perform in inflationary periods2026 Key Lessons & Daily Stock Momentum Reports - baoquankhu1.vn
Context Therapeutics to Present Poster at AACR Annual Meeting - National Today
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 - The Manila Times
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context will show preclinical CT-202 tumor data at April cancer meeting - Stock Titan
Loss Report: Is Context Therapeutics Inc stock risky to hold now2026 Dividend Review & Expert Curated Trade Ideas - baoquankhu1.vn
HR Positive/ HER2 Negative Breast Cancer Clinical Trial - openPR.com
HR Positive/ HER2 Negative Breast Cancer Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart
CNTX PE Ratio & Valuation, Is CNTX Overvalued - Intellectia AI
H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka
Context Therapeutics Outlines Post-ADC T-Cell Engager Strategy, Teases Q2 Claudin 6 Data - MarketBeat
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):